Mounjaro 5mg
€150
Mounjaro 5mg biedt veel voordelen voor het beheer van diabetes en het bevorderen van gewichtsverlies, ondersteund door robuuste klinische bewijs. Altijd de prioriteit van professioneel medisch advies om te zorgen voor een veilig en effectief gebruik.
Product Beschrijving
Mounjaro 5mg
Mounjaro 5 mg (tirzepatide) is an FDA-approved prescription injectable medication indicated to improve glycemic control in adults with type 2 diabetes mellitus. Used alongside diet and exercise, Mounjaro 5 mg represents the primary therapeutic step-up dose following the initial 2.5 mg starter phase, offering enhanced glycemic management and supporting weight loss outcomes.
Dual-Action Mechanism: How Mounjaro 5 mg Works
Mounjaro is a first-in-class dual glucose-dependent insulinotropic polypeptide ($\text{GIP}$) and glucagon-like peptide-1 ($\text{GLP-1}$) receptor agonist. By simultaneously activating both gut hormone receptors, tirzepatide optimizes metabolic regulation:
-
Insulin Secretion: Enhances glucose-dependent insulin release from pancreatic beta cells during elevated blood sugar levels.
-
Glucagon Suppression: Reduces liver glucose production by lowering post-meal glucagon secretion.
-
Satiety & Digestion: Delays gastric emptying and acts on brain satiety centers to promote fullness and reduce daily caloric intake.
Dosering en toedieningsrichtlijnen
Mounjaro 5 mg is administered once weekly via a pre-filled, single-dose auto-injector pen.
| Kernparameter | Medisch advies |
| Beheer | Subcutaneous injection into the abdomen, thigh, or upper arm. |
| Titration Schedule | Initiated only after completing 4 consecutive weeks on the 2.5 mg starter dose. |
| Dosing Frequency | Administer once weekly, on the same day, at any time of day, with or without food. |
Note: Rotate injection sites with each weekly dose to reduce the risk of localized skin irritation.
Veelvoorkomende bijwerkingen en veiligheidswaarschuwingen
While Mounjaro 5 mg provides powerful therapeutic benefits, patients must stay informed regarding potential adverse effects and health precautions.
Common Gastrointestinal Effects
-
Nausea, diarrhea, and vomiting
-
Decreased appetite and indigestion (dyspepsia)
-
Constipation and abdominal pain
Critical Health Precautions
-
Thyroid C-Cell Tumor Risk: Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
-
Pancreatitis Risk: Monitor for severe, persistent abdominal pain radiating to the back; discontinue immediately if suspected.
-
Hypoglycemia Risk: Increased when co-administered with sulfonylureas or insulin.



